The role of cell culture vaccines in the control of the next influenza pandemic

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 709-717

  Audsley, J M ^a   Tannock, G A ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Cell culture; Influenza; Pandemic; Vaccine

Indexed keywords

CELL CULTURE VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

AVIAN INFECTIOUS BRONCHITIS VIRUS; CELL CULTURE; CELL GROWTH; CELL STRAIN; CHICK EMBRYO; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE PREDISPOSITION; EGG; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; PATHOGENICITY; REVIEW; SPECIES DIFFERENCE; VACCINATION; VERO CELL; VIROGENESIS; VIRUS CULTURE; VIRUS STRAIN;

ANIMALS; CELLS, CULTURED; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, SYNTHETIC;

AVES; AVIAN INFECTIOUS BRONCHITIS VIRUS; GALLUS GALLUS; INFLUENZA A VIRUS; INFLUENZA VIRUS;

EID: 2442656479     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.709     Document Type: Review

References (62)

1. WILSON IA, COX NJ: Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. (1990) 8:737-771.
2. SHAW MW, ARDEN NH, MAASSAB HF: New aspects of influenza viruses. Clin. Microbiol. Rev. (1992) 5:74-92.
3. POTTER CW: Unique features of influenza viruses, and their implications. Semin. Respir. Infect. (1992) 4:216-223.
4. ADA GL, TANNOCK GA, HAMPSON AW: Conference Report: Options for the control of influenza III. Vaccine (1997) 15:245-247.
5. WEBSTER RG, BEAN WJ, GORMAN OT, CHAMBERS TM, KAWAOKA Y: Evolution and ecology of influenza A viruses. Microbiol. Rev. (1992) 56:152-179.
6. TAUBENBERGER JK, REID AH, KRAFFT AE, BIJWAARD KE, FANNING TG: Initial genetic characterization of the 1918 'Spanish' influenza virus. Science (1997) 275:1793-1797.
7. GIBBS MJ, ARMSTRONG JS, GIBBS AJ: Recombination in the haemagglutinin gene of the 1918 'Spanish Flu'. Science (2001) 293:1842-1845.
8. KURTZ J, MANVELL JM, BANKS J: Avian influenza virus isolated from a woman with conjunctivitis. Lancet (1996) 348:901-902.
9. SUBBARAO K, KLIMOV A, KATZ J et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 279:393-396.
10. YUEN KY, CHAN PKS, PEIRIS M et al.: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet (1998) 351:467-471.
11. SHORTRIDGE KF: Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: Abridged chronology and virus isolation. Vaccine (1999) 17:S26-S29.
12. TAM JS: Influenza A (H5N1) in Hong Kong: an overview. Vaccine (2002) 20:S77-S81.
13. LIN YP, SHAW M, GREGORY V et al.: Avian-to-human transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates. Proc. Natl. Acad. Sci. USA (2000) 97:9654-9658.
14. PEIRIS M, YUEN KY, LEUNG CW et al.: Human infection with influenza H9N2. Lancet (1999) 354:916-917.
15. GUO YJ, LI J, CHENG X et al.: Discovery of men infected by avian influenza A (H9N2) virus. Chin. J. Exp. Clin. Virol. (1999) 13(2):105-108.
16. ANONYMOUS: Influenza A (H5N1) in Hong Kong Special Administrative Region of China - Update 2. WHO - Disease Outbreak News (2003) 27 February 2003,
17. KOOPMANS M, FOUCHIER R, WILBRINK B et al.: Update on human infections with highly pathogenic avian influenza virus A/H7N7 during an outbreak in poultry in the Netherlands. Eurosurveillance Weekly (2003) 7:1.
18. ANONYMOUS: Influenza A (H9N2) in Hong Kong Special Administrative Region of China (SAR). WHO - Disease Outbreaks Notification (2003) 10 December 2003.
19. ANONYMOUS: Avian influenza A (H5N1) in humans in Vietnam. WHO - Disease Outbreak News (2004) 13 January 2004.
20. WILLIAMS MS, WOOD JM: A brief history of inactivated influenza virus. In: Options for the Control of Influenza II. Hannoun C (Ed.), Elsevier Science Publishers, Amsterdam (1993):169-170.
21. BREDE HD: Influenza vaccines. Int. Arch. Allergy Immunol. (1995) 108:318-320.
22. COUCH RB: Advances in influenza virus vaccine research. Ann. NY Acad Sci. (1993) 685:803-812.
23. PIEDRA PA: Influenza virus pneumonia: Pathogenesis, treatment and prevention. Semin. Respir. Infect. (1995) 4:216-223.
24. WAREING MD, TANNOCK GA: Live attenuated vaccines against influenza; an historical review. Vaccine (2001) 19:3320-3330.
25. MAASSAB HF, HEILMAN CA, HERLOCHER ML: Cold-adapted influenza viruses for use as live vaccines in man. Adv. Biotechnol. Processes (1990) 14:203-242.
26. KENDAL AP: Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. (1997) 13:591-609.
27. KENDAL AP, MAASSAB HF, ALEXANDROVA GI, GHENDON YZ: Development of cold-adapted recombinant live, attenuated influenza A vaccines in the USA and USS.R. Antiviral Res. (1981) 1:339-365.
28. SHORTRIDGE KF, ZHOU NN, GUAN Y et al.: Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology (1998) 252:331-342.
29. SENNE DA, PANIGRAHY B, KAWAOKA Y et al.: Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis. (1996) 40:425-427.
30. LI S, LIU C, KLIMOV A et al.: Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. (1999) 179:1132-1138. A report of the first recombinant reassorted H5N1 vaccine with the multibasic HA cleavage site associated with virulence excised.
31. HATTA M, GAO P, HALFMANN P, KAWAOKA Y: Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science (2001) 293:1840-1842.
32. MEYER WJ, WOOD JM, MAJOR D et al.: Influence of host-cell mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology (1993) 196:130-137.
33. LEHMANN-GRUBE F: Influenza viruses in cell cultures. II. Use of calf kidney cells for quantal assay. Arch. Gesamte Virusforschung (1964) 14:177-188.
34. ZAMBON M: Cell culture for surveillance of influenza. Dev. Biol. Stand. (1999) 98:65-71.
35. KLENK H-D, ROTT R, ORLICH M, BLÖDORN J: Activation of influenza A viruses by trypsin treatment. Virology (1975) 68:426-439.
36. TANNOCK G, BRYCE DA, PAUL JA: Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza master strain A/Ann/Arbor/6/60-ca. Vaccine (1985) 3:333-339.
37. GOVORKOVA EA, KAVERIN NV, GUBAREVA LV, MEIGNIER B, WEBSTER RG: Replication of influenza A viruses in a Green monkey kidney continuous cell line (Vero). J. Infect. Dis. (1995) 172:250-253.
38. TOBITA K, SUGIURA A, ENOMOTO C, FURUYAMA M: Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. (1975) 162:9-14.
39. GAUSH CR, HARD WL, SMITH TF: Characterization of an established line of canine kidney cells (MDCK). Proc. Soc. Exp. Biol. Med. (1966) 166:931-935.
40. MEGURO H, BRYANT JD, TORRENCE AE, WRIGHT PF: Canine kidney cell line for isolation of respiratory viruses. J. Clin. Microbiol. (1979) 9:175-179.
41. AUDSLEY JM: Egg-free substrates for the growth of live, attenuated influenza vaccine viruses: an evaluation of two continuous cell lines for the growth of cold-adapted donor strains. In: Department of Applied Biology & Biotechnology. RMIT, Melbourne, Australia (1998):77.
42. GOVORKOVA EA, KODIHALLI S, ALYMOVA IV, FANGET B, WEBSTER RG: Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated eggs. Dev. Biol. Stand. (1999) 98:39-51.
43. MERTEN OW, HANNOUN C, MANUGUERRA JC, VENTRE F, PETRES S: Development of a serum-free cell culture based human influenza virus vaccine production process. In: Novel Strategies in the Design and Production of Vaccines. Cohen S, Shafferman A (Eds), Plenum Press, New York, USA (1996):141-151.
44. MONTAGNON BJ: Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev. Biol. Stand. (1989) 70:27-47.
45. NO AUTHORS LISTED: Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. (1995)73:431-435. WHO report recommending further developmental studies for the use of cell culture for influenza vaccines.
46. BRANDS R, PALACHE AM, VAN SCHARRENBURG GJM: Madin Darby canine kidney (MDCK) - cells for the production of inactivated influenza subunit vaccine. Safety characteristics and clinical results in the elderly. In: Options for the Control of Influenza III. Brown LE (Ed.), Elsevier Science, Amsterdam (1996):683-693.
47. BRUHL P, KERSCHBAUM A, KISTNER O et al.: Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine (2001) 19:1149-1158.
48. HALPERIN SA, NESTRUCK A, EASTWOOD JE: Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine (1998) 16:1331-1335.
49. PALACHE AM, SCHEEPERS HSJ, DE REGT V et al.: Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. (1999) 98:115-125.
50. LASMEZAS CI, FOURNIER J-G, NOUVEL V et al: Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: Implications for human health. Proc. Natl. Acad. Sci. USA (2001) 98:4142-4147.
51. GRIFFITHS JB: Serum and growth factors in cell culture media - an introductory review. Dev. Biol. Stand. (1987) 66:155-160.
52. MERTEN OW: Development of serum-free media for cell growth and production of viruses/viral vaccines - safety issues of animal products used in serum-free media. Dev. Biol. Stand. (2002) 111:233-257. A detailed review of the current developments and issues involved in the design and production of serum-free and protein-free media.
53. PAU MG, OPHORST C, KOLDIJK MH et al.: The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine (2001) 19:2716-2721.
54. MERTEN OW, MANUGUERRA JC, HANNOUN C, VAN DER WERF S: Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand. (1999) 98:23-37.
55. FALLAUX FJ, BOUT A, VAN DER VELDE I et al.: New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. (1998) 9:1909-1917.
56. KATZ JM, WEBSTER RG: Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. (1989) 160:191-198.
57. KATZ JM, WEBSTER RG: Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J. Gen. Virol. (1992) 73:1159-1165.
58. TREANOR JJ, WILKINSON BE, MASSEOUD F et al.: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine (2001) 19:1732-1737.
59. WHO: Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses - Interim biosafety risk assessment. Department of Communicable Disease Surveillance and Response (2003). The latest WHO report detailing standards for avian influenza reassortant vaccine viruses and their production.
60. ANONYMOUS: St. Jude develops vaccine against potential pandemic HSN1 using reverse genetics. In: Vaccine Weekly (2003):22.
61. NICHOLSON C, MAJOR D, WOOD JM, ROBERTSON JS: Generating epidemic and pandemic vaccine strains by reverse genetics. Options for the Control of Influenza V. Okinawa, Japan (2003).
62. WRIGHT PF, THOMPSON J, VAUGHN WK et al.: Trials of influenza A/ New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. Infect. Dis. (1977) 136:S731-S741.